receptor targets raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-05-27. Anything still debated is marked as such rather than presented as settled.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
冻干粉通常在低温环境下保存，复溶之后需要按指定条件在较短时间内使用。反复冻融和剧烈振荡可能促进聚集，低吸附容器则能减少多肽在管壁上的损失。批号、日期与处理条件的完整记录，是后续复核与问题追溯的基础。
供应环节涉及来源核实与文件审核两类工作。分析证书、批次记录以及第三方检测报告构成常见的可追溯材料。来源不清的样品很难确认身份与纯度，因此核实步骤在实际操作中具有明确意义。缺少方法细节的报告通常无法复核。
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Not a small molecule |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist activity |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also in aqueous buffers |
| Storage | −20 °C or below | Protect from light and moisture |
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
== Medical uses == Tralokinumab is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy. In the United States, tralokinumab is indicated for the treatment of moderate-to-severe atopic dermatitis in adults whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
A hematoma, also spelled haematoma, or blood suffusion is a localized bleeding outside of blood vessels, due to either disease or trauma including injury or surgery and may involve blood continuing to seep from broken capillaries. A hematoma is benign and is initially in liquid form spread among the tissues including in sacs between tissues where it may coagulate and solidify before blood is reabsorbed into blood vessels. An ecchymosis is a hematoma of the skin larger than 10 mm. They may occur among and or within many areas such as skin and other organs, connective tissues, bone, joints and muscle. A collection of blood (or even a hemorrhage) may be aggravated by anticoagulant medication (blood thinner). Blood seepage and collection of blood may occur if heparin is given via an intramuscular route; to avoid this, heparin must be given intravenously or subcutaneously.
== First ministry == The first Bjelke-Petersen ministry was sworn in by Governor Alan Mansfield on 8 August 1968, and served until the reconstitution of the Ministry on 29 May 1969. It was almost unchanged from the Pizzey Ministry and Chalk Ministry. Max Hodges was appointed to fill the cabinet vacancy caused by Jack Pizzey's death, and the roles vacated by Bjelke-Petersen on becoming Premier.
Throughout West Africa, Indigo was the foundation of centuries-old textile traditions. From the Tuareg nomads of the Sahara to Cameroon, clothes dyed with indigo signified wealth. Women dyed the cloth in most areas, with the Yoruba of Nigeria and the Mandinka of Mali particularly well known for their expertise. Among the Hausa male dyers, working at communal dye pits was the basis of the wealth of the ancient city of Kano, and they can still be seen plying their trade today at the same pits. The Tuareg are sometimes called the "Blue People" because the indigo pigment in the cloth of their traditional robes and turbans stained their skin dark blue. Palestine and Iran also historically produced large amounts of indigo. In Palestine, it was a major industry since at least the 17th century. It was used to dye southern women's dresses, coats in Galilee, pants all over, and men's cloaks. A similar blue-to-black shift occurred due to British colonialism, though blue is still seen on traditional Palestinian dresses with some frequency in synthetic form. Widows would dye their dresses with indigo to cover the other colors, and wear blue veils and belts. Blue was also associated with unmarried girls, whose dresses were embroidered with it.
Sources: en.wikipedia.org
=== Development === On January 31, 2023, it was announced that a remake version of Matlock was in development, and Jennie Snyder Urman signed on to write a pilot episode to be aired by CBS. Urman is expected to executive produce alongside Joanna Klein, Eric Christian Olsen, and Kathy Bates. On May 9, 2023, the Matlock remake was given a series order. The series is developed by Urman. John Will and Kat Coiro were added as executive producers. Coiro also directed the pilot. Production companies involved with the series are Sutton Street, Cloud Nine, and CBS Studios. Matlock was moved to the 2024–25 season due to strike-related production delays. It was later reported that it was a 19-episode order. On October 22, 2024, CBS renewed the series for a second season. Though set in New York City, the show is filmed at Paramount Studios in California after the pilot was shot in Toronto. On January 22, 2026, CBS renewed the series for a third season.
Rimexolone is a glucocorticoid steroid used to treat inflammation in the eye. It is marketed as a 1% eye drop suspension under the trade name Vexol by Alcon Laboratories, but was discontinued in the US and other countries.
Osteomimicry occurs when cancer cells begin to express genes normally restricted to cells present within the bone. These genes include osteocalcin, osteopontin, bone sialoprotein, osteonectin, RANK ligand (NF-κB receptor activator) and parathyroid hormone related peptide (PTHrP). This change in gene expression allows cancer cells to avoid detection by the immune system and establish colonies in the bone microenvironment. Cancer cells expressing these genes secrete normal bone ECM protein products, abnormally altering the bone matrix and activity of osteoblasts and osteoclasts in the local microenvironment.
== The "Discipline" == In the novel, avout follow a life path called the Discipline, sometimes referred to as Cartasian Discipline, after Saunt Cartas, the founder of the mathic world. It is a set of rules governing what is (and is not) allowed for avout to know and/or do, and was codified centuries before the time of the story in the Second New Revised Book of Discipline. Chief among these is that the avout are separated from the Sæculum, or outside world. There are different levels of separation. For example, within a concent, there are different terms of residency. There are 1-, 10-, 100-, and 1,000-year orders. Each of these celebrates "Apert", a festival opening the concent to the outside world and allowing the flow of information between them, on an interval determined by that number. For example, a 10-year order would celebrate Apert once every ten years, remaining isolated otherwise. Likewise, a 100-year order would only celebrate Apert every hundred years, and a 1,000-year order once every 1,000 years. It is an essential part of this that at any time an order celebrates Apert, all orders below it also celebrate Apert. For example, a Millenarian (1,000-year) order would celebrate in the year 3000. Because 3000 is also a multiple of 100, 10, and 1, Centenarian, Decenarian, and Unarian orders would also celebrate. Exceptions to this rule include "hierarchs" (those who administer the concent) who are required to confer with the Sæcular Power on decisions of weight.
March: Decree on feudal successions, abolishing primogeniture and affirming gender equality in inheritance. May–June: Decree establishing relief workshops for beggars, differentiated by sex, age, and health (women and children assigned to spinning rather than agricultural workshops). August: Requirement for public prosecutor's hearing if a married woman (or ward, minor, or legally incapacitated person, male or female) is involved in judicial proceedings.
Sources: en.wikipedia.org
On 2 January, Lula revoked a bill made during the Bolsonaro government, which created schools exclusively for persons with disabilities, with the revocation of this law, these students are now able to study in the same schools as other students, while keeping the need for special treatment in some severe cases. On 11 January, Lula signed in a bill called the "National Digital Education Policy", which deals with expanding access to digital education in the country. Another measure taken by the government was the increase in the amount for research grants, Lula later stated that "this government is forbidden to treat [as] wasted money what goes to education, money that goes to scholarships, money that goes to healthcare and research". On 10 March, Lula announced a readjustment in the values of the school meals of public schools, after having been frozen for more than five years. The increase is 39% and the value is 5.5 billion per year. In April, after severe pressure from Student and Teacher unions, the Ministry of Education announced the temporary suspension of the "New High School" programme, however, there was no revocation of the project, and it would later be reinstated in August by Minister of Education Camilo Santana, although with some changes. Also in April, Lula announced that the government would invest over 6 billion in a project to restart the construction of several works in the education area, such as public schools.
=== Research === AM-1006 – undefined mechanism of action (short-acting subperceptual psychoactive drug) – substance use disorders EQL-101 – undefined mechanism of action (non-hallucinogenic non-cardiotoxic ibogaine derivative) – substance use disorders – Equulus Therapeutics Ibogaine – various actions, oneirogen/hallucinogen – substance-related disorders Mebufotenin (5-MeO-DMT; LSR-2000) – non-selective serotonin receptor agonist, serotonin 5-HT1A and 5-HT2A receptor agonist, serotonergic psychedelic – alcoholism MYCO-004 (patch-delivered tryptamine compound) – undefined mechanism of action, serotonergic psychedelic – smoking withdrawal, substance-related disorders Research programme: Ibogaine derivatives - MindMed/Nextage Therapeutics – various actions – opioid-related disorders Research programme: monoclonal antibody therapeutics - CounterX Therapeutics – undefined mechanism of action – opioid-related disorders Research programme: psychedelic and empathogenic compounds subcutaneous - Bexson Biomedical – undefined mechanism of action – substance-related disorders Substance-related disorders therapeutics - Tessara Therapeutics/Xylo Bio/University of Sydney – neuronal plasticity modulators – substance-related disorders VVZ-2471 – metabotropic glutamate mGlu5 receptor antagonist, serotonin 5-HT2A receptor antagonist – opioid-related disorders
== Biological activity == 17α-OHP is an agonist of the progesterone receptor (PR) similarly to progesterone, albeit weakly in comparison. In addition, it is an antagonist of the mineralocorticoid receptor (MR) as well as a partial agonist of the glucocorticoid receptor (GR), albeit with very low potency (EC50 >100-fold less relative to cortisol) at the latter site, also similarly to progesterone.
A practical consequence of redundancy is that some errors in the genetic code cause only a synonymous mutation, or an error that would not affect the protein because the hydrophilicity or hydrophobicity is maintained by equivalent substitution of amino acids (conservative mutation). For example, a codon of NUN (where N = any nucleotide) tends to code for hydrophobic amino acids, NCN yields amino acid residues that are small in size and moderate in hydropathy, and NAN encodes average size hydrophilic residues. These tendencies may result from the shared ancestry of the aminoacyl tRNA synthetases related to these codons. These variable codes for amino acids are allowed because of modified bases in the first base of the anticodon of the tRNA, and the base-pair formed is called a wobble base pair. The modified bases include inosine and the Non-Watson-Crick U-G basepair.
In Indonesia the third-generation Familia was marketed by Indomobil Group twice, the first time as the 323 hatchback from 1977 to 1980, and the second time around as the low-cost alternative of the popular Toyota Kijang and fellow Indomobil Group product's Suzuki Carry Extra/Futura; low-price "Mazda MR90" (hatchback) between December 1990 to 1993, "Mazda Baby Boomers" (hatchback) between 1993 and 1995, and as the "Mazda Vantrend" (station wagon and special limited order as high roof van or pickup) between 1993 and 1997. The Vantrend and its derivatives were also marketed as the Mazda M1400. The name MR90 stands for "Mobil Rakyat 90" (people's car for the 1990s) as it was intended to become a national car project. This was scuppered by the appearance of the Timor 515 project. The MR90 and its successors did see limited exports to small markets such as Fiji and Sri Lanka. There was also a better equipped GLX version available. The Baby Boomers was a lightly facelifted variant with new bumpers and a rear spoiler, for a more sporty appearance overall. The 1990s versions built by Indomobil have modernized headlights (same as on the Mazda 626 (GC), while Vantrend adopted the pre-facelift North American market quad headlights version) and bumpers. These alterations mean that the overall length increased, up to 3,970 mm (156 in) for the MR90 hatchback. Only the 70 PS (51 kW) UC 1.4-litre engine was offered, in combination with a five-speed transmission.
Sources: en.wikipedia.org
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.
Earlier incretin therapies engage one or two receptors. Retatrutide adds glucagon receptor activity, which may raise energy expenditure. Whether this produces larger clinical benefits is still being tested.
It has completed phase 2 trials and moved into later-stage evaluation. No regulator has granted approval. Access outside research settings is not authorized.
常用质谱测定分子量，再结合肽图或序列分析验证一级结构。单一检测手段一般难以排除结构相近的类似物。多种方法相互印证更为可靠。